The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Suzanne Schindler
Project Title: Alzheimer’s Disease Blood-Based Biosignature for Predicting Clinical Progression
Date: February 4, 2026 at 9:06 am
Request ID: T2603
Aim 1: Generate and validate a biosignature for: Cognitively unimpaired individuals (CU) who progress to mild cognitive impairment (MCI) at 24 months based on a contrast between two groups: CU individuals who remain cognitively unimpaired at 24 months CU individuals who progress to MCI at 24 month
Aim 2: Generate and validate a biosignature for: Individuals with MCI who progress to dementia at 24 months based on a contrast between two groups: Individuals with MCI who remain classified as MCI at 24 months Individuals with MCI who progress to dementia at 24 months
Aim 3: To evaluate the association between baseline biomarkers and magnitude of cognitive and functional decline.
Aim 4:
Investigator: Susan Acton
Project Title: Characterization of LPAR3 expression in the Alzheimer’s Brain
Date: February 2, 2026 at 8:10 am
Request ID: T2602
Aim 1: Determine where LPAR3 is expressed in the human AD brain
Aim 2: Determine if LPAR3 is expressed in different brain locations in healthy controls vs. three CDR stages of AD (0.5, 1, & 2)
Aim 3: Determine if LPAR3 may be expressed in different brain locations by age (<55 yrs vs. 70-80 yrs)
Aim 4:
Investigator: Soumya Mukherjee
Project Title: Distribution of big tau isoform across CNS and PNS, and of Aβ, ApoE and tau PTMs across multiple brain regions
Date: January 18, 2026 at 11:53 am
Request ID: T2601
Aim 1: Measure tau (small and big tau) and Aβ isoforms across multiple brain regions
Aim 2: Measure Aβ, ApoE and tau PTMs across multiple brain regions
Aim 3:
Aim 4:
Investigator: Jessica Mozersky & Sarah Hartz
Project Title: Evaluation of plasma phosphorylated tau in the Knight ADRC cohort
Date: January 8, 2026 at 7:36 pm
Request ID: T2515-A
Aim 1: Compare & map plasma p-tau 217% measures from the Bateman lab to plasma p-tau 217% those from C2N
Aim 2:
Aim 3:
Aim 4:
Investigator: Andrew Yoo
Project Title: Modeling Neuronal Aging and Alzheimer’s Disease via 3D Direct Reprograming of Patient Fibroblast
Date: January 7, 2026 at 5:20 pm
Request ID: T2508-A
Aim 1: Testing the effect of SORL1 variants on APP processing in directly reprogrammed human neurons
Aim 2:
Aim 3:
Aim 4:
Investigator: Nupam Mahajan
Project Title: Therapeutic Targeting of the Alzheimer’s Disease by Novel ACK1 Inhibitor (R)-9b
Date: December 17, 2025 at 5:32 pm
Request ID: T2524
Aim 1: Preclinical evaluation of pY827-ACK1 and pY394-Tau as novel therapeutic targets in AD
Aim 2:
Aim 3:
Aim 4:
Investigator: Zerui Wang
Project Title: Spatial and Cellular Mapping of α-Synuclein Seeding Activity in Human Synucleinopathies Using an In Situ Quiescent Seed Amplification Assay (QSAA)
Date: December 16, 2025 at 12:38 pm
Request ID: T2523
Aim 1: Construct spatial maps of α-synuclein seeding activity in human synucleinopathies
Aim 2: Define the cellular localization of α-synuclein seeding activity using IF-QSAA
Aim 3: Correlate functional seeding activity to classical α-synuclein pathology
Aim 4:
Investigator: Agnes Cheong
Project Title: Comprehensive Alzheimer’s Disease Research Initiative: Integrating Spatial Proteomics, Pathological Mechanisms, and Novel Therapeutic Target Discovery
Date: December 12, 2025 at 1:27 pm
Request ID: T2522
Aim 1: Neurite Protection Against Patient-Derived Bioactive Amyloid-Beta Species: Identifying Novel Therapeutic Targets for Alzheimer’s Disease and related diseases
Aim 2: Understanding Tau Pathology Heterogeneity: Implications for Targeted Therapeutic Strategies in Alzheimer’s Disease
Aim 3: Spatial molecular mapping of Alzheimer’s disease brain via MALDI-tMSI
Aim 4:
Investigator: Zhao Sun
Project Title: Dissecting molecular mechanism associated with the onset of late-onset neurodegenerative diseases.
Date: November 24, 2025 at 11:14 am
Request ID: T2521
Aim 1: Aim 1. Define the transcriptional and chromatin landscapes that distinguish healthy aging from pathological aging in LOAD neurons. With approval from the Alzheimer’s Disease Research Center at Washington University in St. Louis (hereafter “WashU ADRC”), we will obtain fibroblast lines from individua
Aim 2: Aim 2. Test partial rejuvenation can slow or reverse disease progression in LOAD. We will determine whether attenuating normal healthy aging can slow or reverse disease onset and progression in LOAD. To do this, we will apply partial epigenetic reprogramming (by transient Yamanaka-factor expression
Aim 3:
Aim 4:
Investigator: Gwendalyn Randolph
Project Title: Volumetric Mapping of Immune – Vascular Disruption in Human Cerebral Amyloid Angiopathy by ADAPT – 3D
Date: November 6, 2025 at 6:03 pm
Request ID: T2520
Aim 1: Determine the 3D spatial relationship between Aβ accumulation and BAM spatial reorganization and correlate these findings with available antemortem neuroimaging and fluid biomarkers.
Aim 2: Establish the volumetric correlation of vascular failure (smooth muscle cell loss and microhemorrhage) and validate these metrics against antemortem MRI/PET data and systemic biomarkers.
Aim 3:
Aim 4: